About

I am an award-winning writer, editor, photographer and designer with more than 30 years of experience in the media. After studying at the University of Leeds, then London and Anglia HEC, I moved to Canada in the 1980s and started out on the radio while also writing for various music and sports publications, and doing freelance photography. I then edited some magazines before working at a science organization, doing communications and editing publications in a programming language called LaTeX that was challenging but exciting.

Following that, I edited a newspaper, spent some time in the US, and then moved back to the UK where I edited a food B2B publication.
I’ve written, and taken photographs for, hundreds of publications around the world, as well as for books, album covers, DVDs, and shot coverage for documentaries. I’ve edited books, written nine of my own, and done redesigns for several publications. And now I’m writing about biotech, as well as creating videos and a weekly podcast.

I’ve done other things, like running an aquarium, teaching photography and drumming (not at the same time), and running football (soccer) refereeing courses.

In what spare time I have, I love spending time with my wife, son and dog, challenging hikes up the Scottish hills (and down again), playing and writing music, watching baseball and soccer, and collecting memorabilia and autographs.

Articles by Jim Cornall

Alentis Therapeutics raises $105M for claudin platform

New technique developed for safer gene editing  

PsychoGenics launches eCube AI platform for drug discovery

Sumitomo Pharma Oncology receives orphan drug designation for Ewing sarcoma treatment

Calida Therapeutics launches to tackle thrombo-inflammatory disorders

Intracellular drug delivery startup Vitarka Therapeutics raises £1.27M

ADVERTISEMENT

InflaRx receives emergency use authorization for critically ill COVID-19 patients treatment

Ginkgo Bioworks boosts gene therapy capacity with StrideBio asset acquisition

Cure Ventures launches with $350M to support life sciences companies

Mosaic Therapeutics closes $28M series A funding

BioNTech adds antibody-drug conjugates to cancer portfolio with potential $1.5B partnership deal

Alzamend pushing ahead with Alzheimer’s vaccine trial

ADVERTISEMENT